Bioshares latest addition included an update on Opthea.
Here are a few edited highlights. Opthea is building a compelling case for its ophthalmology drug candidate,OPT-302. Having delivered positive results in the first indication of wet AMD in a PhaseIb/IIa trial last year, it has now produced early positive data from its Phase Ib/IIa study indiabetic macular edema. It is also strengthening the scientific rationale that underpinsits technology, which will support a future commercial transaction of OPT-302.
In relation to the DME trial. In the five patients with bilateral disease, Opthea plus Eylea achieved a mean 10 lettergain in vision compared to only a 2.6 letter improvement in patients receivingEylea in the second eye. The combinationtreatment achieved a central subfield thickness reduction of 80uM compared to just a 6uM reduction in theEylea only treatment alone.
It was also explained why the mechanism of action of OPT-302 may have efficacy in DME
The company expects to receive a $12 million tax rebate forlast financial year.
Although data for its two trials is between 12 - 18 months away,investors with patience may be very well rewarded with this stock.The company's core asset OPT-302 has the potential to deliversubstantial value to the company if positive trial data continues to flow.
- Forums
- ASX - By Stock
- OPT
- Ann: Opthea Reports Positive Data from Ph1b DME Study of OPT-302
Ann: Opthea Reports Positive Data from Ph1b DME Study of OPT-302, page-5
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OPT (ASX) to my watchlist
|
|||||
Last
47.5¢ |
Change
-0.020(4.04%) |
Mkt cap ! $594.0M |
Open | High | Low | Value | Volume |
49.5¢ | 50.8¢ | 47.5¢ | $4.304M | 9.050M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 29597 | 47.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
48.5¢ | 15044 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 29597 | 0.475 |
4 | 69173 | 0.470 |
1 | 15044 | 0.465 |
1 | 18645 | 0.460 |
3 | 20931 | 0.455 |
Price($) | Vol. | No. |
---|---|---|
0.485 | 15044 | 2 |
0.490 | 15044 | 1 |
0.500 | 1540 | 1 |
0.505 | 1970 | 1 |
0.510 | 66230 | 3 |
Last trade - 16.10pm 20/08/2024 (20 minute delay) ? |
Featured News
OPT (ASX) Chart |
The Watchlist
CC9
CHARIOT CORPORATION LTD
MD - Shanthar Pathmanathan, Geologist - David Trabert
MD - Shanthar Pathmanathan
Geologist - David Trabert
SPONSORED BY The Market Online